Gene correction in hematopoitic stem cells using a retargetable meganuclease

描述(申请人提供)：用于细胞分裂的持续性基因疗法，如造血干细胞，通常需要将治疗性转基因整合到染色体中，例如，使用逆转录病毒。这种方法有几个缺点，包括在不适当的位置整合可能导致癌症，以及缺乏适当的基因调控元件。相比之下，通过同源重组进行基因打靶，可以将转基因置于基因组中预定的、安全的位置。利用基因打靶进行基因治疗的困难在于，它在大多数细胞中很少发生。然而，以前的研究表明，在靶点引入双链断裂可以使哺乳动物细胞中的同源重组频率增加多达五个数量级。这项建议旨在定义诱导基因靶向的最佳方法，该方法使用一种可重定向的内切酶，该酶特异性地切割小鼠基因组中的rosa26基因位点。Rosa26是一个理想的转基因表达部位，因为它是普遍表达的，并且不是必需的。内切酶来源于ICrel酶，具有足够的特异性，能够靶向哺乳动物基因组中的特定位置，并且具有足够的可变性，可以针对大多数基因座进行设计。首先，将证明工程内切酶在小鼠细胞系中诱导基因靶向的能力。绿色荧光蛋白将作为转基因模型。其次，将确定在保持造血干细胞重建髓鞘个体血液能力的同时诱导造血干细胞基因纠正的最佳方法。最后，将开发在移植前基于培养扩增和流式细胞仪分选的方法来增加造血细胞移植中正确靶向细胞的比例。目前旨在从基因上治愈某些遗传性血液疾病的方法存在缺陷，如致癌的可能性和低效。这项提案寻求定义新的方法，以更准确地纠正导致这些疾病的遗传突变，从而消除目前基因治疗方案的一些危险和缺点。

DESCRIPTION (provided by applicant): Persistent gene therapy in dividing cells such as hematopoietic stem cells generally requires that the therapeutic transgene be integrated into a chromosome, for example, using a retrovirus. There are several drawbacks to this approach, including the possibility that integration at an inopportune locus can cause cancer, and a lack of appropriate gene regulatory elements. In contrast, gene targeting by homologous recombination allows one to place a transgene into a predetermined, safe, location in the genome. The difficulty in making use of gene targeting for gene therapy is that it occurs only rarely in most cells. However, it has previously been shown that introducing a double strand break at the site to be targeted can increase the homologous recombination frequency by up to five orders of magnitude in mammalian cells. This proposal seeks to define optimal methods for inducing gene targeting with a retargetable endonuclease that specifically cuts at the ROSA26 locus in the mouse genome. ROSA26 is an ideal site for transgene expression because it is ubiquitously expressing and non-essential. The endonuclease is derived from the ICrel enzyme and has sufficient specificity to be able to target particular sites in a mammalian genome, and is sufficiently modifiable that it can be designed to target most loci. First, the ability of the engineered endonuclease to induce gene targeting in mouse cell-lines will be demonstrated. Green fluorescent protein will be used as a model transgene. Second, optimal methods to induce gene correction in hematopoietic stem cells while maintaining their ability to reconstitute the blood of a myelpablated individual will be determined. Finally, methods for increasing the fraction of correctly targeted cells in a hematopoietic cell transplant, based on expansion in culture and selection with flow cytometry sorting prior to transplant, will be developed. Current methods aimed at genetically curing certain inherited blood diseases have drawbacks, such as the possibility of causing cancer and low efficacy. This proposal seeks to define new methods to more precisely correct the inherited mutations that cause these disorders, thereby eliminating some of the dangers and disadvantages of current gene therapy protocols.